Drug intelligence / Profile preview

VM206Ad

Development stage: Unknown
Lead developer: Reyon Pharmaceutical
Modality: Vaccines & Immunotherapeutics, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies
Administration: Intramuscular

Overview

VM206Ad is a biological, adenoviral vector-based therapeutic vaccine component developed by Reyon Pharmaceutical. It is designed to deliver and express the HER2/neu (ErbB2) antigen to stimulate a targeted immune response against HER2-positive cancer cells. VM206Ad is used as part of the VM206RY regimen, a heterologous prime-boost strategy that combines this adenoviral vector with a DNA plasmid vaccine (VM206DNA). The drug is administered via intramuscular injection and has been investigated in Phase I clinical trials for patients with HER2-expressing breast cancer.

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on VM206Ad.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VM206Ad.

Explore the full profile